Skip to main content
. 2018 Jan 10;38(1):BSR20171302. doi: 10.1042/BSR20171302

Figure 3. Survival and pathological hypertrophy in advanced iron-overload cardiomyopathy.

Figure 3

(A) Kaplan–Meier survival curves for control (HJVKO-control), iron overload (HJVKO-iron + placebo), and resveratrol rescue (HJVKO-iron + RSV). (B) Heart (HW), LV, and hepatic (liver) weights in control, iron overload, and after resveratrol therapy adjusted to tibia length (TL) or body weight (BW). (C) Expression levels of heart failure markers in control, iron overload, and after resveratrol therapy: ANF, BNP, and β-MHC. (D) Wheat germ agglutinin (WGA) staining: representative images and quantitation of myocardial cross-sectional area (MCSA) in control, iron overload, and after resveratrol therapy. n=8 hearts per group (B–D).*P<0.05 compared with the control group; #P<0.05 compared with the iron group. Abbreviations: Ctl, HJV control; Fe, iron diet; Fe + R, iron diet + resveratrol.